Sheehan, DV, Harnett-Sheehan, K. The role of SSRIs in panic disorder.
J Clin Psychiatry
1996; 57 (suppl 10):
Toni, C, Perugi, G, Frare, F, Mata, B, Vitale, B, Mengali, F, et al. A prospective naturalistic study of 326
panic-agoraphobic patients treated with antidepressants.
2000; 33: 121–31.
Westenberg, HG. Developments in the drug treatment of panic
disorder: what is the place of the selective serotonin reuptake
J Affect Disord
National Institute for Health and Clinical Excellence.
Anxiety: Management of Anxiety (Panic Disorder, With or Without
Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary,
Secondary and Community Care.
Baldwin, D, Anderson, I, Nutt, D, Bandelow, B, Bond, A, Davidson, JR, et al. Evidence-based guidelines for the
pharmacological treatment of anxiety disorders: recommendations from the
British Association for Psyhcopharmacology. J
2005; 19: 567–96.
Hood, SD, Argyropoulos, SV, Nutt, DJ. New directions in the treatment of anxiety
disorders. Expert Opinion Ther Patents
2003; 13: 401–23.
Phillips, B, Ball, C, Sackett, D, Badenoch, D, Straus, S, Haynes, B, et al. Oxford Centre for Evidence-based Medicine Levels of
Food and Drug Administration. Worsening depression
and suicidality in patients being treated with antidepressant.
FDA Public Health Advisory,
Culpepper, L, Davidson, JR, Dietrich, AJ, Goodman, WK, Kroenke, K, Schwenk, TL. Suicidality as a possible side effect of
antidepressant treatment. Prim care companion. J
Amsterdam, JD, Hornig-Rohan, M, Maislin, G. Efficacy of alprazolam in reducing
fluoxetine-induced jitteriness in patients with major
depression. J Clin Psychiatry
Ramos, RT, Gentil, V, Gorenstein, C. Clomipramine and initial worsening in panic
disorder: beyond the ‘jitteriness syndrome’. J
1993; 7: 265–9.
Yeragani, VK, Pohl, R, Balon, R, Ramesh, C, Weinberg, P. Imipramine-induced jitteriness and decreased serum
iron levels. Neuropsychobiology
Beasley, CM Jr, Sayler, ME, Bosomworth, JC, Wernicke, JF. High-dose fluoxetine: efficacy and
activating-sedating effects in agitated and retarded
depression. J Clin Psychopharmacol
1991; 11: 166–74.
Beasley, CM Jr, Sayler, ME, Weiss, AM, Potvin, JH. Fluoxetine: activating and sedating effects at
multiple fixed doses. J Clin
1992; 12: 328–33.
Harada, T. A survey of activation syndrome induced by
antidepressants. Int Clin
2006; 21: A9.
Giesecke, ME. Overcoming hypersensitivity to fluoxetine in a
patient with panic disorder. Am J
1990; 147: 532–3.
Gorman, JM, Liebowitz, MR, Fyer, AJ, Goetz, D, Campeas, RB, Fyer, MR, et al. An open trial of fluoxetine in the treatment
of panic attacks. J Clin Psychopharmacol
1987; 7: 329–32.
Louie, AK, Lewis, TB, Lannon, RA. Use of low-dose fluoxetine in major depression and
panic disorder. J Clin Psychiatry
1993; 54: 435–8.
Perlis, RH, Beasley, CM Jr, Wines, JD, Tamura, RN, Cusin, C, Strong, RE, et al. Treatment-associated suicidal ideation and
adverse effects in an open, multicenter trial of fluoxetine for major
depressive episodes. Psychother
2007; 76: 40–6.
Schneier, FR, Liebowitz, MR, Davies, SO, Fairbanks, J, Hollander, E, Campeas, R, et al. Fluoxetine in panic disorder.
J Clin Psychopharmacol
1990; 10: 119–21.
Aronson, TA. A naturalistic study of imipramine in panic disorder
and agoraphobia. Am J Psychiatry
1987; 144: 1014–9.
Pohl, R, Yeragani, VK, Balon, R, Lycaki, H. The jitteriness syndrome in panic disorder patients
treated with antidepressants. J Clin
1988; 49: 100–4.
Zitrin, CM, Klein, DF, Woerner, MG. Behavior therapy, supportive psychotherapy,
imipramine, and phobias. Arch Gen
1978; 35: 307–16.
Jackson, CW, Lydiard, RB. Two cases of activation/jitteriness associated with
TCAs. J Clin Psychopharmacol
1990; 10: 439–40.
Noyes, JR R, Garvey, MJ, Cook, BL, Samuelson, L. Problems with tricyclic antidepressant use in
patients with panic disorder or agoraphobia: results of a naturalistic
follow-up study. J Clin Psychiatry
1989; 50: 163–9.
Pohl, R, Yeragani, VK, Ortiz, A, Rainey, JM Jr, Gershon, S. Response of tricyclic-induced jitteriness to a
phenothiazine in two patients. J Clin
1986; 47: 427.
Lotufo-Neto, F, Bernik, M, Ramos, RT, Andrade, L, Gorenstein, C, Cordas, T, et al. A dose-finding and discontinuation study of
clomipramine in panic disorder. J
2001; 15: 13–7.
Ackerman, DL, Greenland, S, Bystritsky, A. Side effects as predictors of drug response in
obsessive-compulsive disorder. J Clin
1999; 19: 459–65.
Guile, JM. Sertraline-induced behavioral activation during the
treatment of an adolescent with major depression.
J Child Adolesc Psychopharmacol
1996; 6: 281–5.
Oehrberg, S, Christiansen, PE, Behnke, K, Borup, AL, Severin, B, Soegaard, J, et al. Paroxetine in the treatment of panic
disorder. A randomised, double-blind, placebo-controlled
study. Br J Psychiatry
1995; 167: 374–9.
Vorstman, J, Lahuis, B, Buitelaar, JK. SSRIs associated with behavioral activation and
suicidal ideation. J Am Acad Child Adolesc
2001; 40: 1364–5.
Liegghio, NE, Yeragani, VK, Moore, NC. Buspirone-induced jitteriness in three patients with
panic disorder and one patient with generalized anxiety
disorder. J Clin Psychiatry
1988; 49: 165–6.
Pohl, R, Balon, R, Yeragani, VK, Gershon, S. Serotonergic anxiolytics in the treatment of panic
disorder: a controlled study with buspirone.
1989; 22 (suppl 1):
Tollefson, GD, Sayler, ME. Course of psychomotor agitation during
pharmacotherapy of depression: analysis from double-blind controlled
trials with fluoxetine. Depress Anxiety
Stahl, SM, Mendels, J, Schwartz, GE. Effects of reboxetine on anxiety, agitation, and
insomnia: results of a pooled evaluation of randomized clinical
trials. J Clin Psychopharmacol
2002; 22: 388–92.
Pohl, RB, Wolkow, RM, Clary, CM. Sertraline in the treatment of panic disorder: a
double-blind multicenter trial. Am J
1998; 155: 1189–95.
Hu, XH, Bull, SA, Hunkeler, EM, Ming, E, Lee, JY, Fireman, B, et al. Incidence and duration of side effects and
those rated as bothersome with selective serotonin reuptake inhibitor
treatment for depression: patient report versus physician
estimate. J Clin Psychiatry
2004; 65: 959–65.
Zajecka, J, Amsterdam, JD, Quitkin, FM, Reimherr, FW, Rosenbaum, JF, Tamura, RN, et al. Changes in adverse events reported by
patients during 6 months of fluoxetine therapy. J
1999; 60: 389–94.
Edwards, JG, Anderson, I. Systematic review and guide to selection of
selective serotonin reuptake inhibitors.
1999; 57: 507–33.
Lipinski, JF Jr, Mallya, G, Zimmerman, P, Pope, HG Jr. Fluoxetine-induced akathisia: clinical and
theoretical implications. J Clin
1989; 50: 339–42.
Akagi, H, Kumar, T. Akathisia: overlooked at a cost.
2002; 324: 1506–7.
Tollefson, G, Rampey, A, Beasley, CM Jr, Enas, G, Potvin, JH. Absence of a relationship between adverse events and
suicidality during pharmacotherapy for depression.
J Clin Psychopharmacol
1994; 14: 163–9.
Vorstman, J, Lahuis, B, Buitelaar, J. SSRIs Associated with behavioural activation and
suicidal ideation. J Am Acad Child Adolesc
2001; 40: 1364–5.
Putzhammer, A, Schoeler, A, Rohrmeier, T, Sand, P, Hajak, G, Eichhammer, P. Evidence of a role for the 5-HTTLPR genotype in the
modulation of motor response to antidepressant treatment.
2005; 178: 303–8.
Perlis, RH, Mischoulon, D, Smoller, JW, Wan, YJ, Lamon-Fava, S, Lin, KM, et al. Serotonin transporter polymorphisms and
adverse effects with fluoxetine treatment. Biol
2003; 54: 879–83.
Murphy, GM Jr, Kremer, C, Rodrigues, HE, Schatzberg, AF. Pharmacogenetics of antidepressant medication
intolerance. Am J Psychiatry
2003; 160: 1830–5.
Balon, R. Selective serotonin reuptake inhibitors and suicide:
is the evidence, as with beauty, in the eye of the
2003; 72: 293–9.
Westenberg, HG, Den Boer, JA. New findings in the treatment of panic
1993; 26 (suppl 1):
Liebowitz, MR, Klein, DF. Differential diagnosis and treatment of panic
attacks and phobic states. Annu Rev
1981; 32: 583–99.
Argyropoulos, SV, Sandford, J, Nutt, DJ. The psychobiology of anxiolytic drugs. Part 2:
pharmacological treatments of anxiety. Pharmacol
Ther 200; 88: 213–27.
Scott, A, Davidson, A, Palmer, K. Antidepressant drugs in the treatment of anxiety
disorders. Advan Psychiatr Treat
2001; 7: 275–82.
Lane, RM. SSRI-induced extrapyramidal side-effects and
akathisia: implications for treatment. J
Yeragani, VK, Pohl, R, Balon, R. Tricyclics, akathisia, and
jitteriness. J Clin Psychopharmacol
1988; 8: 295.
Ener, RA, Meglathery, SB, Van Decker, WA, Gallagher, RM. Serotonin syndrome and other serotonergic
disorders. Pain Med
Sachdev, P, Kruk, J. Restlessness: the anatomy of a neuropsychiatric
symptom. Aust N Z J Psychiatry
Weller, IVC. Report of the CSM Expert Working Group on the Safety of
Selective Serotonin Reuptake Inhibitor Antidepressants.
Medicines and Healthcare Regulatory
Bagdy, G, Graf, M, Anheuer, ZE, Modos, EA, Kantor, S. Anxiety-like effects induced by acute fluoxetine,
sertraline or m-CPP treatment are reversed by pretreatment with the
5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor
antagonist WAY-100635. Int J